tetano
Editor, Senior Moderator
Viruses
. 2021 Nov 19;13(11):2306.
doi: 10.3390/v13112306.
Kite-Shaped Molecules Block SARS-CoV-2 Cell Entry at a Post-Attachment Step
Shiu-Wan Chan[SUP] 1 [/SUP], Talha Shafi[SUP] 1 [/SUP], Robert C Ford[SUP] 1 [/SUP]
Affiliations
Abstract
Anti-viral small molecules are currently lacking for treating coronavirus infection. The long development timescales for such drugs are a major problem, but could be shortened by repurposing existing drugs. We therefore screened a small library of FDA-approved compounds for potential severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antivirals using a pseudovirus system that allows a sensitive read-out of infectivity. A group of structurally-related compounds, showing moderate inhibitory activity with IC[SUB]50[/SUB] values in the 2-5 μM range, were identified. Further studies demonstrated that these "kite-shaped" molecules were surprisingly specific for SARS-CoV-1 and SARS-CoV-2 and that they acted early in the entry steps of the viral infectious cycle, but did not affect virus attachment to the cells. Moreover, the compounds were able to prevent infection in both kidney- and lung-derived human cell lines. The structural homology of the hits allowed the production of a well-defined pharmacophore that was found to be highly accurate in predicting the anti-viral activity of the compounds in the screen. We discuss the prospects of repurposing these existing drugs for treating current and future coronavirus outbreaks.
Keywords: COVID-19; SARS-CoV-2; anti-viral screening; pharmacophore; pseudovirus; spike protein; virus attachment; virus entry; virus post-attachment.
. 2021 Nov 19;13(11):2306.
doi: 10.3390/v13112306.
Kite-Shaped Molecules Block SARS-CoV-2 Cell Entry at a Post-Attachment Step
Shiu-Wan Chan[SUP] 1 [/SUP], Talha Shafi[SUP] 1 [/SUP], Robert C Ford[SUP] 1 [/SUP]
Affiliations
- PMID: 34835112
- DOI: 10.3390/v13112306
Abstract
Anti-viral small molecules are currently lacking for treating coronavirus infection. The long development timescales for such drugs are a major problem, but could be shortened by repurposing existing drugs. We therefore screened a small library of FDA-approved compounds for potential severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antivirals using a pseudovirus system that allows a sensitive read-out of infectivity. A group of structurally-related compounds, showing moderate inhibitory activity with IC[SUB]50[/SUB] values in the 2-5 μM range, were identified. Further studies demonstrated that these "kite-shaped" molecules were surprisingly specific for SARS-CoV-1 and SARS-CoV-2 and that they acted early in the entry steps of the viral infectious cycle, but did not affect virus attachment to the cells. Moreover, the compounds were able to prevent infection in both kidney- and lung-derived human cell lines. The structural homology of the hits allowed the production of a well-defined pharmacophore that was found to be highly accurate in predicting the anti-viral activity of the compounds in the screen. We discuss the prospects of repurposing these existing drugs for treating current and future coronavirus outbreaks.
Keywords: COVID-19; SARS-CoV-2; anti-viral screening; pharmacophore; pseudovirus; spike protein; virus attachment; virus entry; virus post-attachment.